DVAX

Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company founded in 1996 and headquartered in Emeryville, California. Originally incorporated as Double Helix Corporation, the company changed its name to Dynavax Technologies Corporation in September 1996 and went public in 2004. Dynavax has evolved from a research-stage company into a commercial-stage biopharmaceutical enterprise focused on developing and commercializing novel vaccines. The company achieved significant commercial success with its hepatitis B vaccine HEPLISAV-B and has built a robust pipeline of vaccine candidates leveraging its proprietary CpG 1018 adjuvant technology.